1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Clostridium Difficile Infection (CDI) - Epidemiology Forecast to 2024

EpiCast Report: Clostridium Difficile Infection (CDI) - Epidemiology Forecast to 2024

Summary

Clostridium difficile infections (CDI) are primarily transmitted through the fecal-oral route. There are two major sources of CDI: healthcare-associated CDI (HA-CDI) and community-associated CDI (CA-CDI). The typical clinical symptoms of CDI range from watery diarrhea, anorexia, and nausea, to hypoalbuminemia and abdominal tenderness in severe cases. Though suspected in all patients with antibiotic-associated diarrhea, the confirmatory diagnosis of CDI is primarily based on the combination of clinical features exhibited by the patient and the results of various laboratory tests including stool tests, as well as, in certain rare scenarios, endoscopy or radiologic tests. Recurrence and complications of CDI usually pose grave challenges for the treatment and management of this condition and occur in about 20-30% of the patients treated successfully for their first episode.

GlobalData epidemiologists predict that the diagnosed incident cases of all-CDI will grow from 686,540 cases in 2014 to 825,021 cases in 2024, at an Annual Growth Rate (AGR) of 2.02% over the 10-year forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of all-CDI in the 7MM.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years). The term all-CDI is defined as any instance of suspected CDI and diarrhea, with stool samples testing positive for toxin A, B, or both (enzyme immunoassay [EIA], cytotoxicity test, or polymerase chain reaction [PCR]) or revealing the presence of toxin-producing C. difficile, and includes both HA-CDI and CA-CDI. The report also provides the 10-year epidemiology forecast for the all-CDI cases segmented by epidemiological association into HA-CDI and CA-CDI. Additionally, the report provides a 10-year epidemiological forecast for the recurrent all-CDI cases with a further segmentation by number of recurrences.

Scope

- The Clostridium difficile infection (CDI) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for CDI in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all-CDI segmented by sex and by age (in five-year age groups beginning at 18 years and ending at =85 years).
- The CDI epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Clostridium Difficile Infection (CDI) EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CDI market.
- Quantify patient populations in the global CDI market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CDI therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Clostridium Difficile Infection (CDI) - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 13
3.3.1 7MM: Diagnosed Incidence Rates 15
3.3.2 7MM: Diagnosed Incident Cases by Epidemiological Association 16
3.3.3 7MM: Diagnosed Incident Cases by Recurrences 16
3.4 Forecast Methodology 17
3.4.1 Sources Used 19
3.4.2 Sources Not Used 25
3.4.3 Forecast Assumptions and Methods 28
3.5 Epidemiological Forecast of CDI (2014-2024) 34
3.5.1 Diagnosed Incident Cases of All-CDI 34
3.5.2 Age-Specific Diagnosed Incident Cases of All-CDI 36
3.5.3 Sex-Specific Diagnosed Incident Cases of All-CDI 38
3.5.4 Age-Standardized Diagnosed Incidence Rate of All-CDI 40
3.5.5 Recurrent CDI Cases 42
3.5.6 Diagnosed Incident Cases of All-CDI by Epidemiological Association 43
3.6 Discussion 45
3.6.1 Epidemiological Forecast Insight 45
3.6.2 Limitations of the Analysis 47
3.6.3 Strengths of the Analysis 47
4 Appendix 48
4.1 Bibliography 48
4.2 About the Authors 55
4.2.1 Epidemiologists 55
4.2.2 Reviewers 55
4.2.3 Global Director of Therapy Analysis and Epidemiology 57
4.2.4 Global Head of Healthcare 57
4.3 About GlobalData 58
4.4 About EpiCast 58
4.5 Disclaimer 59

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for CDI 12
Table 2: Definitions of CDI Segmentations 18
Table 3: 7MM, Sources of CDI Diagnosed Incidence Data 19
Table 4: 7MM, Sources of CDI Recurrence Rates 20
Table 5: 7MM, Sources of CDI Epidemiological Association 20
Table 6: 7MM, Sources Not Used in Epidemiological Analysis of CDI 27
Table 7: 7MM, Diagnosed Incident Cases of All-CDI, Ages ?18 Years, Both Sexes, N, Selected Years 2014-2024 35
Table 8: 7MM, Age-Specific Diagnosed Incident Cases of All-CDI, Ages ?18 Years, Both Sexes, N, 2014. 37
Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ?18 Years, N, 2014 39

1.2 List of Figures
Figure 1: Incidence Rate for CDI in the 7MM, 2014 14
Figure 2: Case Flow Map for the US 21
Figure 3: Case Flow Map for the 5EU and Japan 22
Figure 4: 7MM, Diagnosed Incident Cases of All-CDI, Ages ?18 Years, Both Sexes, N, 2014-2024 36
Figure 5: Age-Specific Diagnosed Incident Cases of All-CDI, Ages ?18 Years, Both Sexes, N, 2014 38
Figure 6: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ?18 Years, N, 2014 40
Figure 7: 7MM, Age-Standardized Diagnosed Incidence Rates of All-CDI, 2014 41
Figure 8: 5EU and Japan, Recurrent CDI Cases, Ages ?18 Years, N, 2014 42
Figure 9: US, Diagnosed Incident Cases of CDI Stratified by Recurrence, Ages ?18 Years, N, 2014 43
Figure 10: 5EU and Japan, Diagnosed Incident Cases of All-CDI Stratified by Epidemiological Association, Ages ?18 Years, N, 2014 44
Figure 11: US, Diagnosed Incident Cases of All-CDI by Epidemiological Association, Ages ?18 Years, N, 2014 45

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.